



University
of Basel

Faculty of
Medicine



ECPM – European Center of Pharmaceutical Medicine

Institute of Pharmaceutical Medicine

Annual Report 2025.



ECPM[®] 
European Center of Pharmaceutical Medicine

CONTINUING
EDUCATION

Table of Contents

Foreword.	3
Introduction	3
The ECPM at a glance.	4
ECPM Educational Mission	4
ECPM Research Activities	4
Facts & Figures – ECPM in 2025	4
ECPM Educational Offers	5
Organizational chart.	6
European Center of Pharmaceutical Medicine.	7
Institute of Pharmaceutical Medicine.	7
Director	7
Education & Training.	8
Personnel.	8
Head of Education & Training, Managing Director	8
Course Director	9
Course Coordinator	9
Research.	11
Personnel.	11
Head of Research	11
Senior Research Scientist	12
Senior Research Scientist	12
PhD Candidate	15
PhD Candidate	16
PhD Candidate	16
Manager Research Group	17
Scientific Assistant	17
External Collaborator	17
Education & Training.	18
Current Status.	18
Undergraduate / Graduate Teaching	18
Postgraduate Training	18
The following postgraduate courses were offered in 2025:	19
Education & Training.	20
Objectives for the coming years.	20
Education & Training.	21
ECPM Training Opportunities	21
ECPM Certificate and Diploma Course (CAS, DAS) in Pharmaceutical Medicine	21
Master Course (MAS) in Medicines Development	21
Frontiers in Drug Development Seminars	22
Examination	22
Multiple choice examination (MCQ):	22
Oral/Essay examination:	22
E-learning	23
Electronic Learning Platform	23
Education & Training Projects in 2025	23
Planned Education & Training Projects for 2026	23
PharmaTrain Board	24
Undergraduate Teaching at the University of Basel Medical School	24
Undergraduate Teaching at the University of Basel, Faculty of Science	24
Undergraduate Teaching at the University of Zurich	24
Undergraduate Teaching at the University of Bern	25
Postgraduate Teaching at the University of Basel	25
Postgraduate Teaching at the University of Zurich	25
Research.	26
Current Status.	26
Key Areas of Expertise	26
Research.	27
Objectives for the coming years.	27
Research.	28
Overview of activities.	28
Local academic collaborations	28
Collaborations with national and international academic and public entities	28
Collaborations with private entities	28
Research.	29
Upcoming Projects: outlook 2026.	29
Research.	30
New Projects (started in 2025).	30
Research.	31
Ongoing projects.	31
Research.	36
Completed projects.	36
Activities of the ECPM collaborators in 2025.	
Publications, Scientific Presentations, Evaluation of Research Projects and Thesis Supervision.	38
Scientific Presentations to External Audiences	42
Evaluation of Research Projects and Publications (peer review)	45
PhD Theses Supervised by the ECPM Collaborators in 2025	45
Master Theses: MD	45
Master Theses: MBA, MMD and MPH	45

Foreword.

Driving Impact in Pharmaceutical Education and Research

Introduction

The European Center of Pharmaceutical Medicine (ECPM) at the University of Basel plays a leading role in postgraduate education and research in medicines development and health economics. In response to rapid advances in areas such as artificial intelligence, digital health, and gene editing, ECPM provides specialized education and training to ensure pharmaceutical professionals remain up to date with evolving industry demands.

This report explores the vital contributions of the European Center for Pharmaceutical Medicine (ECPM) in Switzerland and its international partners. ECPM offers a broad portfolio of postgraduate programs, including CAS, DAS, MAS, and continuing professional development (CPD) courses in pharmaceutical medicine and medicines development. Its programs cover the full lifecycle of drug development, from clinical trials and regulatory affairs to healthcare marketing and project management.

The institution also promotes innovation in education through topics such as AI in drug development, digital transformation, and data science. Planned developments for 2026 include new courses in health economics, market access, AI applications, and modular offerings for start-ups and spin-offs.

ECPM's research activities, embedded within the Department of Public Health, focus on health

technology assessment, health economic evaluation, health services research, epidemiology, biostatistics, and behavioral economics. Over the past two decades, ECPM has become one of Switzerland's most active health economics research groups, supported by substantial external funding and numerous international collaborations.

A major milestone has been the establishment of the Health Economics Facility (HEF) and the interfaculty Basel Center for Health Economics (BCHE), which strengthen interdisciplinary collaboration across the University of Basel and external partners. These initiatives support large-scale research projects, expand educational opportunities, and reinforce the role of health economics within the medical faculty.

ECPM is involved in several major European and Swiss research initiatives, including EU HORIZON projects and investigator-initiated clinical trials funded by the Swiss National Science Foundation. Current research topics include cost-effectiveness analyses, health services research, causal inference using real-world data, and studies on gender bias in oncology treatment decisions.

Overall, ECPM combines high-quality education, interdisciplinary collaboration, and internationally recognized research to advance pharmaceutical medicine, health economics, and healthcare innovation in Switzerland and beyond.



Prof. Thomas D. Szucs
Director



Dr. Annette Mollet
Head of Education & Training



Prof. Matthias Schwenkglenks
Head of Research

The ECPM at a glance.



Number of students

(1991–2025)

2305



Nationalities of students

(2025–2027)

21



Faculty Members

(overall)

150

ECPM Educational Mission

Our mission at ECPM is to establish the best international training platform that provides and enhances the knowledge, expertise and skills required to perform modern discovery, development, regulation and marketing of medical products.

ECPM Research Activities

The Research department started its activities in 2003, with a focus on health economic characteristics, cost-benefit implications and efficient use of pharmaceuticals and other healthcare interventions in Switzerland and internationally. We maintained our position as one of the most active health technology assessment, health economics and health services research groups in Switzerland, with a high level of publication activity and co-operations with multiple partners.

Facts & Figures – ECPM in 2025

- Performed Modules 5 and 6 and thus completed our 17th Diploma Course Cycle with 108 participants (more than 2100 since the initiation of the program)
- Started our 18th Diploma Course Cycle with Module 1 in September.
- Awarded 14 CAS, 52 DAS and 11 FMH specialist titles.
- Represented ECPM at the Drug Information Association (DIA) Europe Conference in Basel.
- Represented ECPM at the AI and Digital Health Conference at Novartis.
- Collaborated with 150 faculty members from different affiliations
- Annette Mollet became an Honorary Member of the Swiss association of Pharmaceutical Professionals.
- Thomas Szucs published his new book *Gen-Recht in der Schweiz*.
- Published a new book chapter 'Educating Future Leaders in Drug Development About AI' in the textbook 'Medical Education in the Age of Digital Transformation'
- Was involved in graduate and postgraduate teaching of 10 different programs
- Received more than 800,000 Swiss Francs in third-party research funding
- Started the health economic part of the "ClassIntra® for Better Outcomes in Surgery – CIBOSurg" quality improvement project coordinated by University Hospital Basel and run in 9 Swiss hospitals.
- Acquired a Cancer Research Switzerland grant for the health economic evaluation of the SAKK 96/12 trial studying the prevention of symptomatic skeletal-related events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial
- Continued to provide research expertise in health economic evaluations, budget impact analysis, health technology assessment, health services and outcomes, insurance claims data, systematic reviews and meta-analysis, applied behavioral economics, epidemiology, and biostatistics
- Trained undergraduate and graduate students from medicine, pharmacy, human biology, public health and nursing
- Supervised 3 PhD students in Basel, 1 PhD student at the UFL – Private University in the Principality of Liechtenstein, 1 MAS student
- Authored and co-authored around 40 published peer-reviewed articles and multiple conference abstracts
- Gave multiple scientific presentations to external audiences
- Welcomed new education and research staff

ECPM Educational Offers

Since our foundation in 1991, we have trained over 2,300 students holding MDs, PhDs or an MSc, and recruited 150 members of faculty. Furthermore, since the introduction of the Bologna system in 2000, ECPM was proud to upgrade from awarding a certificate to the possibility of awarding a postgraduate diploma. From 2009 to 2014, Fritz R. Bühler, Thomas D. Szucs, Susanne Daniel and Annette Mollet led the Innovative Medicines Initiative (IMI) project – a public/private partner-


ship called PharmaTrain. Through this European academic network, the ECPM training platform was taken to the next level to offer a postgraduate Master title. The postgraduate master program (MAS) was inaugurated in 2015 and builds upon the diploma course adding additional courses which can be chosen individually and the elaboration of a master thesis.

Educational background of students
(2025 – 2027)



MD	29%
MD PhD	9%
MBA, MA Economics	8%
PhD Biotechnology	13%
PhD Pharmacy	8%
PhD Chemistry	7%
MSc Biology	4%
MSc Chemistry	3%
MSc Pharmacy	4%
MSc Life Science	4%
MSc Communication	3%
BSc Biology	3%
MSc Veterinary	1%
MSc MD	3%
BSc Chemistry	1%
Total	100.0%

Workplace of students
(2025 – 2027)




Small to Medium Size Pharma	24%
Big Pharma Top 20	47%
CROs, Expert Services	3%
Regulator	3%
Hospitals	10%
Venture Capital	1%
Academia	5%
Biotech	7%
Total	100%

Teaching Faculty
(2025 – 2027)



Big Pharma	31%
Small and Medium Sized Enterprises	9%
CRO	7%
Regulatory Authorities	20%
Academia/ University Hospitals	23%
Consultants	9%
Total	100%

Organizational chart.



European Center of Pharmaceutical Medicine. Institute of Pharmaceutical Medicine.



Director

Thomas D. Szucs, MD MBA MPH LL.M JSD joined ECPM in 2003 and was appointed Professor of Pharmaceutical Medicine and Director of The Institute of Pharmaceutical Medicine/European Center of Pharmaceutical Medicine at the University of Basel in 2009.

He is also a Professor and part-time lecturer for Medical Economics at the University of Zurich and an honorary professor at the University of Peking Health Science Center. Previously he was Chief Medical Officer of Hirslanden Holding, the largest private hospital chain in Switzerland.

From 1998 to 2001, he was head of the Department of Medical Economics, a joint venture of the University Hospital in Zurich and the Institute of Social and Preventive Medicine of the University of Zurich. Professor Szucs' former appointments include head of research and founder of the Center of Pharmacoeconomics of the University of Milan, head of the working group for Clinical Economics at the University of Munich, senior consultant at Arthur D. Little Inc. and head of the Department of Health Economics at F. Hoffmann-La Roche Ltd. in Basel.

He holds a medical degree from the University of Basel, a Master in Business Administration from the University of St Gallen, Switzerland, a Master of Public Health degree from Harvard University, a LL.M in International Business Law from the University of Zurich and a Doctorate in Law from the Private University of Liechtenstein. Thomas is board certified in Pharmaceutical Medicine as well as in Prevention and Public Health.

He is also member of the editorial board of several scientific journals. So far, he has published more than 400 articles, book chapters and monographs. He has worked extensively in the field of pharmaceutical economics and epidemiology. From 2004–2014 he was the president of the Swiss Association of Health Economics. In 2010, he was appointed Chairman of Helsana Insurance, Ltd, the largest health insurer in Switzerland, a posi-

tion he held until December, this year. In 2016, Professor Szucs was rated among the 20 most influential economists in Switzerland. In 2020, he was recognized as a Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. Since 2013, he started to work as a clinician in genomic medicine. In 2020, he was appointed as Co-Director Genomic Medicine at the Hirslanden Private Hospital Group, which consists of 17 hospitals.

Education & Training. Personnel.

The European Center of Pharmaceutical Medicine (ECPM), founded in 1991, has established a reputation as one of the premier European training centers in Pharmaceutical Medicine. The ECPM training platform offers undergraduate/graduate training for medical and life sciences students and postgraduate training on three different levels in the field of Pharmaceutical Medicine/Drug Development Sciences.

The first postgraduate level represents the ECPM Certificate/Diploma of Advanced Studies course, (CAS 20 ECTS/DAS 30 ECTS), which can then be complemented on a second level with Continuing

Professional Development (CPD) short courses. The third level involves a thesis to achieve the Master of Advanced Studies in Medicines Development (MAS, 60 ECTS).

We collaborate locally with the Department of Clinical Research at the University Hospital in Basel and University of Zurich, as well as Europe wide with universities in the PharmaTrain network, such as the Kings College London, United Kingdom, and internationally with the Peking University Clinical Research Institute at the University of Beijing, University of San Francisco.



Head of Education & Training, Managing Director

Annette Mollet, PhD, dipl. Pharm. Med. SwAPP, MBA is Managing Director and Head of Education & Training of the ECPM at the University of Basel since 1997.

Annette holds a Master in Pharmacy from the University of Basel and a PhD in Neurobiology from the Swiss Federal Institute of Technology in Zurich and an MBA in International Health from the Swiss Tropical and Public Health Institute (Swiss TPH). She teaches drug development both at the Universities of Basel and Zurich. In 1997 Annette joined the clinical R&D department at F. Hoffmann-La Roche in Basel. as a research scientist and moved later to Roche Pharma Schweiz to work as a Medical and Product Manager for oncology products..

She was chairing the Federal Expert Committee for the Evaluation of Radioactive Drugs, a joint committee of the Swiss Agency for Therapeutic Products (Swissmedic) and the Swiss Federal Office of Public Health (BAG) from 2008, until 2023.. She was a founding member and member of the board of the Swiss Association of Pharmaceutical Professionals (SwAPP) and was active in SwAPP's commission for specialty training and Continuing Professional Education (CPD) from 1999 until 2018.

She was also involved as a Program Manager in the creation of a European specialist title in Pharmaceutical Medicine and of a Master title in Medicines Development within the Innovative Medicines Initiative (IMI) from 2009 until 2014. She is board member of the PharmaTrain Federation (successor project after termination of the PharmaTrain project in 2014).

From 2016–2021, Annette was member of Board of the Association of Graduate Regulatory Educators (AGRE global) based in the USA. She is the co-author of the Dictionary of Pharmaceutical Medicine by Springer (fourth edition, 2017) and was a member of the working party on the “PharmaTrain Syllabus for Pharmaceutical Medicine” lead by the Royal College of Physicians in London. Since April 2017, Annette forms part of the Committee of Continuing Education of the University of Basel. From 2018 until 2022, she was elected External Examiner at the Trinity College of the University of Dublin for the curriculum in Pharmaceutical Medicine.

In 2020, she was recognized as Global Fellow in Medicines Development by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine. From 2021 until 2023, Annette was elected Board

Member of IFAPP (International Federation of Association of Pharmaceutical Physicians and Pharmaceutical Medicine) where she chaired the “Young Professionals” working group. Its objec-

tive is to raise awareness in young people at the beginning of their career, training possibilities and job offerings in the field of Pharmaceutical Medicine.



Course Director

Monika Graff has been Course Director at ECPM since May 2023. She received her BSc in Neuroscience in 2017 from University College London and her MSc in Genomic Medicine in 2019 from Cambridge University, United Kingdom. In 2020, Monika began her PhD thesis in collaboration with Roche Pharmaceuticals where she is carrying out research in artificial intelligence and data sharing. She graduated from the diploma course at ECPM in 2021 and also holds

a professional qualification in genetic counseling. Her clinical training for genetic counseling was completed in Oxford University Hospitals NHS Foundation Trust, Imperial College Healthcare NHS Trust and Great Ormond Street Hospital Trust in the United Kingdom. She was involved in evaluating the role out of Whole Genome Sequencing into the English National Health Service.



Course Coordinator

Nicola Liversidge was responsible for the course coordination at the European Center of Pharmaceutical Medicine from 2023 until July, 2025. She earned a BA in Psychology at Webster University Geneva and a Master's in International Business from Hult University in Shanghai. Previously she worked as a recruiter for CTC Resourcing Solutions, served as Deputy Operative Lead for the Triage and Test Center at the University Hospital of Basel, and has held various positions at Syngenta.

In August 2025, **Noah Murer** took over the role of the course coordinator. He has previously coordinated the graduate school as well as the international master's programs of the Faculty of Business and Economics of the University of Basel.

He holds a MA in Philosophy from the University of Zurich and a BA in Philosophy and History from the University of Basel. His scientific interests lie in philosophy of science and medicine, public health, and clinical ethics.





The Biozentrum of the University of Basel is the training venue for the ECPM post-graduate course program.
Picture: © Atelier Fontana, Basel)

Research. Personnel.

The ECPM's research activities focus on the health economic characteristics, cost-benefit implications and efficient use (e.g. guided by predictive testing or risk stratification models) of pharmaceuticals and other healthcare interventions in Switzerland and internationally. They have a close relationship with modern Health Technology Assessment, and use and integrate health economic and pharmacoeconomic evaluation methodology (cost effectiveness, cost utility, application of advanced modeling techniques), outcomes and clinical research (i.e., randomized clinical trial and observational study) methodology, and biostatistics. Complementary activities occur in related fields such as health systems research, health services research including work with large real-world datasets, clinical epidemiology, pharmacoepidemiology, and behavioral economics.

Health economic evaluation studies, which are a mainstay of ECPM's research activities, integrate

clinical evidence with medical resource use and cost data to analyze the value for money provided by new or long-used drugs and other health care interventions. The overarching question is how scarce health care resources can be optimally used to maximize patient benefit and support the sustainability of healthcare systems. The results of this type of research are an important prerequisite of informed and transparent health policy decision making.

Clinical fields addressed by ECPM studies include, amongst others, oncology and hematology, cardiovascular disease and heart failure, geriatrics, palliative care, neurology, ophthalmology, infectious diseases, and vaccinations.

ECPM's research activities are closely integrated with those of the Health Economics Facility at the Department of Public Health and of the Basel Center for Health Economics.

Head of Research



Matthias Schwenkglens, PhD, MPH has been ECPM's Head of Research since 2003. From 2010 to 2024, he has also led the Medical Economics Unit at the Epidemiology, Biostatistics and Prevention Institute of the University of Zurich. In Basel, Matthias was appointed Research Group Leader at the Department of Public Health, in 2021. In 2022, he was appointed as Head of the newly founded Health Economics Faculty (HEF), which has been endorsed as an integrated part of the Faculty of Medicine's research infrastructure. He also is a founding member and co-director of the interfaculty Basel Center for Health Economics (bche) established in 2023. In 2024, his Titular Professorship in Health Economics and Public Health was transferred from the University of Zurich to the University of Basel, where he is now active full-time. Among other commitments, he acts as a health economics expert for the Cancer Screening Committee set up within the framework of the Swiss National Strategy against Cancer, and as an advisor for the Swiss Healthcare Atlas project led by the OBSAN. Matthias obtained a Master of Arts in Sociology and Political Sciences

from the University of Tübingen, a Master of Public Health from the Universities of Basel, Bern and Zurich, and a PhD in Epidemiology from the University of Basel. In 2009, he received the Venia Legendi in Health Economics and Public Health from the Medical Faculty of the University of Zurich, and was subsequently appointed Professor (Titular Professor) in 2016.

He previously headed the Department of Medical Economics at the Hirslanden Private Hospital Group, Zurich, and worked as a Research Fellow at the Department of Medical Economics of the University of Zurich. He also has extensive professional experience in internal intensive care nursing.

His current research interests and teaching activities are in the fields of health economics, health economic evaluation and modeling, Health Technology Assessment, health services research with large real-world datasets, epidemiology, observational study and trial design, and biostatistics.



Senior Research Scientist

Marina Antillon, PhD has been a Senior Scientist at ECPM since October 2025.

She also works as senior scientist at University of Warwick since December 2024. She has previously held positions at Swiss Tropical and Public Health Institute, University of Antwerp, and University of Chicago.

Her research has involved mathematical simulation modeling, economic evaluations, and statistical methods—including machine learning methods—for uncertainty quantification. Her

therapeutic areas have spanned chronic diseases (cancer, heritable diseases, and migraines) and infectious diseases (screening, vaccination, and elimination). Her research at ECPM focuses on treatment pathways and insurance reimbursement policies.

She holds a PhD in Public Health (Epidemiology of Microbial Diseases) from Yale University, and a BA from University of Chicago where she majored in Environmental Studies and minored in Statistical Methods.



Senior Research Scientist

Michaela Barbier, PhD is a Senior Research Scientist and lecturer at ECPM since 2018.

She holds a Master in Mathematics and Economics (“Wirtschaftsmathematik”) and a PhD in Biostatistics, both from the University of Ulm. Alongside her PhD, she already worked on industry-funded projects in biostatistics but was also involved in teaching activities.

She is an experienced biostatistician with more than 13 years’ expertise in healthcare across academia, the pharmaceutical industry and consulting, with her work spanning health economics and outcomes research, Health Technology Assessments, biostatistics and real world evidence.

Michaela has a vast experience of drug development and clinical trials after working for many years as a (senior) statistician at Novartis. As a later consultant, she expanded her knowledge in health economics with projects ranging from Health Technology Assessments, health economic evaluations and modeling, real world database analyses and also market access. She acquired knowledge of a wide range of indications including among others oncology, cardiovascular, respiratory and ophthalmology.

Her current research interests remain in health economic decision modeling, biostatistical modeling, health service research and value-based health care.



Senior Research Scientist

Mark J. Lambiris has been a senior health economist at ECPM and the Health Economics Facility since 2023.

He previously was a senior health economist at the Swiss Tropical and Public Health Institute. Prior to that he worked as an economist, with big datasets in the areas of health and labour markets and held positions at the University of Lausanne, the Lausanne University Hospital, the Internal Displacement Monitoring Centre in Geneva, the Hellenic Army and in the financial services sector in London.

His has worked extensively on health economic evaluations (cost-effectiveness analyses of drugs or interventions), HTA, the application of causal inference methods to real-world data (health

insurance claims, electronic medical records, social security datasets), implementation research, and evidence synthesis (meta-analysis). His work has spanned multiple disease and health areas, including infectious diseases, antimicrobial resistance, child and cognitive development, mental health, cancer and multiple sclerosis. During his time at ECPM he taught health economics as part of a course aimed at nursing science students and introduction to causal inference to medical students. He also taught statistics and econometrics to Bachelor of Economics students at the University of Lausanne from 2012 to 2017.

He holds a PhD in Economics from the University of Lausanne, a Masters in Economics from the London School of Economics and a Bachelor in Psychology from the University of Surrey.



Senior Research Scientist

Judith Lupatsch, PhD is a Senior Research Scientist and lecturer at ECPM since 2017.

She has a degree in social sciences from the University of Mannheim, where she focused on judgment and decision models as well as behavioral psychology. After working in several projects, she continued with a master's degree in ec0nomics at the University of Bern, where she became interested in econometrics and health economics. Her thesis was on developing and modeling preference-based utility measures for health economic evaluations.

She undertook a PhD in epidemiology and biostatistics at the Institute of Social and Preventive

Medicine (ISPM) in Bern where she had the chance to deepen her modeling and data analysis skills, especially in cancer epidemiology. After the PhD she continued with a post-doctoral fellowship at the institute national de la santé et de la recherche médicale (INSERM) in Paris, France. At the ECPM, she is mainly responsible for health economic and health service research projects in cooperation with the Swiss Group for Clinical Cancer Research (SAKK).

Her current research interests focus on health economics, HTA, epidemiology and health service research, especially modeling aspects.



Senior Research Scientist

Dante Salvador, MD, MPH, PhD is a Research Scientist at ECPM since 2023.

He holds BSc in Biology, Doctor of Medicine, Master in Public Management and initially worked as a health systems manager and rural physician in a remote and resource-limited municipality in central Philippines from 2012 to 2014. The experience inspired him to work and focus in health economics and policy. He completed a dual Masters in Public Health (European Public Health) from University of Sheffield, United Kingdom and Jagiellonian University, Poland through an Erasmus+ scholarship from 2015 to 2017. Since then he has completed several national government projects related to control and prevention of ill-effects of tobacco and alcohol through taxation. He also completed projects for the national health insurance agency in the Philippines from 2018 to 2020.

He moved back to Europe when he was granted a Marie Skłodowska-Curie Actions (MSCA) doctoral training fellowship, and pursued his PhD in Health Sciences (Epidemiology and Biostatistics) at University of Bern wherein he focused on finding associations between diabetes and cardiovascular outcomes, particularly on potential clinical targets measured using cardiovascular MR and carotid ultrasound that are not currently being used as part of clinical guidelines.

After PhD, he started at ECPM to reignite his passion for health economics and health technology assessment, wherein he currently leads several health economic evaluation of clinical trials and public health interventions. Apart from these, he is also interested in improving transparency and communication of health economic studies through reproducible analysis and standardized reporting.



Senior Research Scientist

Nadine Schur, PhD is a Senior Research Scientist at the ECPM since 2015.

She studied Biomathematics at the University of Applied Science Zittau/Goerlitz, Germany, before obtaining a Master of Science in Epidemiology at the University of Basel in 2008. Afterwards, she worked on her PhD thesis “Geostatistical modeling of schistosomiasis transmission in Africa” at the Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute (Swiss TPH), Basel that she published in 2011.

She continued her work at the Swiss TPH on the spatial distribution of neglected tropical diseases in Africa for another year where she was also involved in teaching.

Then, she started a new position as Research Associate at the Department of Infectious Disease Epidemiology, Imperial College London, analyzing demographic and behavior-related factors as well as temporal trends associated with the HIV epidemic in Zimbabwe. She also gained knowledge on the conception and implementation of epidemiological studies in the framework of the Manicaland Project. During her years of research, she has had the opportunity to develop various techniques in health research methodology from systematic reviews to disease modeling.

Her current research interests are in the areas of epidemiology, health economic evaluations and biostatistics focused on multi-variable regression analysis, epidemiological and decision-analytic modeling, and real-world database analyses.



Senior Research Scientist

Sandro Stoffel, PhD is a Senior Research Scientist at ECPM since 2019

He holds a Master in Business Administration from the University of Fribourg, a Master in Development Economics from the University of Rome Tor Vergata and a Master in Economic Theory from Paris-Sorbonne University. After completion of his PhD in Economic Theory at the University of Rome Tor Vergata, he worked as a

Behavioural Researcher at the Joint Research Centre of the European Commission on projects applying insights from behavioral economics to preventive health behaviors. He then moved to UCL and later to the University of Aberdeen, before joining ECPM.

His current research interests are in behavioral health economics, medical decision making and survey methodology.



PhD Candidate

Elia Antonini, MSc, BSc, is a PhD Candidate at ECPM since 2025.

He studied Mathematics at the University of Pisa, Italy, where he obtained a BSc in 2022 and an MSc in 2024. During his studies, he developed a strong interest in mathematical modelling and quantitative methods. He also completed an exchange period at the University of Basel in 2023, where he broadened his background in applied mathematics, data science, and machine learning.

Before joining ECPM, he worked as a Data Scientist at Johnson & Johnson in the Digital & Data Science group, contributing to projects on supply chain risk modelling and pharmaceutical portfolio optimization.

His current PhD research focuses on health economic evaluation, with particular involvement in the SAKK 96/12 and EPIC trials. In SAKK 96/12, a randomized phase III trial in patients with bone metastases from breast or prostate cancer, he works on the cost-effectiveness analysis of alternative denosumab dosing strategies. In EPIC, a multinational stepped-wedge cluster randomized trial on early palliative care in intensive care units, he contributes to the economic evaluation of a complex healthcare intervention. His research interests include trial-based economic evaluation, decision-analytic modelling, Bayesian methods, and quantitative approaches for healthcare decision-making.



PhD Candidate

Niklaus Meier, MSc, BSc, studied economics and applied economic analysis at the University of Bern with a specialization in applied empirical methods in the fields of health and public policy. Through his subsequent work as a research associate for health economics at the Bern University of Applied Sciences, he became familiar with health technology assessment and cost-effectiveness analysis. This experience enabled him to start his PhD at ECPM, under the principal supervision of Matthias Schwenkglenks, in 2021. His PhD focuses on cost-effectiveness analyses of medical interventions for haemophilia with a particular emphasis on treating haemophilia via

gene therapies. For this, he is developing a micro-simulation model to compare potential gene therapies with the current standard of care. Niklaus further plans to conduct a systematic literature review for cost-effectiveness analyses of haemophilia interventions with a focus on reviewing the clinical effectiveness evidence that was used to inform the models. For his final project, he plans to draw on the insights from the previous research to develop or refine methods for cost-effectiveness analyses and specific techniques for quantifying uncertainty and the expected value of information. Niklaus Meier successfully completed his PhD in June 2025.



PhD Candidate

Andri Signorelli, MSc ETH in Mechanical Engineering, studied mechanical engineering at ETH Zurich and subsequently specialized in applied statistics, and health economics through postgraduate training in applied statistics and health economic evaluation. Since 2007, he has been working as a Senior Statistician at Helsana Versicherungen AG, where he gained extensive experience in the analysis of health insurance claims data, epidemiology, and health services research. In parallel, he has been lecturing statistics and financial mathematics at the HWZ University of Applied Sciences in Business Administration Zurich.

He started his PhD at the University of Basel in 2024 under the supervision of Matthias Schwenkglenks. His PhD project, “Parkinson in Switzerland – Prevalence, Risk-Factors, Care”, focuses on epidemiological and health services research related to Parkinson’s disease based on Swiss health insurance claims data. The project aims to estimate the prevalence and incidence of Parkinson’s disease in Switzerland, investigate potential associations with environmental toxicants using spatial statistics, and analyze healthcare utilization, treatment patterns, costs of care, and medication-related risks over time.



Manager Research Group

Beate Kiese, MSc, joined ECPM as Manager Research Group in March 2024.

She holds a Master of Science in Mathematics with special focus on mathematical statistics and chemistry of the University of Münster. Beate has 30 years of experience in the pharmaceutical industry. She worked as a clinical statistician on clinical trials in drug development ranging from phase 1 to phase 3b, and in areas of Oncology, Immunology and other indications. She also worked as portfolio manager for various therapeutic indications in early clinical development for the areas of statistics, programming, data management and medical writing. Later on, she worked as project manager for proj-

ects in clinical trial operations, these projects included for instance the implementation of remote clinical trials and other process improvements for clinical trial conduct. She also has wide experience in interacting with contract research organizations, both in the role as clinical statistician and as Vendor Alliance Manager.

After early retirement she started studying at the University of Basel for a master in Data Sciences, which she pursues in parallel to her role as Manager Research Group. In this role she provides the ECPM research group with operational portfolio management in particular for financial aspects, and general process, cooperation and standardization tasks for the ECPM.



Scientific Assistant

Youssef Akladios, MSc, has been a research scientist at the European Center of Pharmaceutical Medicine since 2024. He received his BSc from the University of Ottawa in 2020 and a Masters in Epidemiology from the Swiss Tropical and Public Health Institute in 2023. During his Master's, he researched Maternal and Child

health, conducting field research in Andean Peru. Previously, he worked at Swiss TPH as a research assistant, focusing on health and economics. His current research interests are in the areas of epidemiology and biostatistics.



External Collaborator

Manuel Werner Luethi, PhD, supports the PREPEC project as external collaborator

He studied economics in Basel and subsequently mathematics at ETH Zurich. He then completed a PhD in pure mathematics under Prof. Manfred Einsiedler. His research focused on dynamical systems and their applications within mathematics, particularly to problems of number theoretic origin.

This was followed by postdoctoral research stays at Tel Aviv University with Barak Weiss and at

EPFL (ETH Lausanne) with Philippe Michel, as well as a position as senior assistant at ETH Zurich. He has published in renowned mathematical journals such as *Inventiones Mathematicae* and *Crelle's Journal*.

Since March 2025, Manuel Luethi has been involved in the PREPEC project as an external collaborator, contributing to statistical modeling and the implementation of the analysis.

Education & Training.

Current Status.

Training is offered at undergraduate, graduate and postgraduate levels. On a postgraduate and Continuing Professional Development (CPD) level, courses provide expert knowledge in drug development, pharmaceutical medicine, clinical research, and regulatory sciences.

The focus of the ECPM training platform is to teach integrated medicines development with emphasis on requirements for rational and rapid development of a new product for the global market. The course programs cover all aspects of pharmaceutical medicine and drug development and regulatory sciences as defined by the IMI PharmaTrain syllabus.

Undergraduate / Graduate Teaching

The ECPM employees teach a variety of graduate-targeted courses in pharmaceutical medicine, health economics and health policy. Courses are offered within the Medical Faculty/ Department of Public Health and the Pharmazentrum of the University of Basel, as well as at the Medical Faculty and Science Faculty of the University of Zurich. Lectures are held in English and German. For details, please refer to the listing of teaching and training activities.

Postgraduate Training

The largest training offer remains the ECPM Diploma Course with approximately 100 participants running over two years. The last course cycle had started in September 2023 and finished in August 2025. with the new course cycle just having started with module 1 in September The course has been offered successfully for 33 years. The Diploma of Advanced Studies in Pharmaceutical Medicine can be extended with Continuing Professional Education (CPD) short courses and a master's thesis to achieve a Master of Advanced Studies in Medicines Development. So far 14 candidates have obtained the master's degree.

In 2012, 2018 and 2024 ECPM received the "Centre of Excellence" accreditation by the Innovative Medicines Initiative (IMI) PharmaTrain. This certifies that ECPM adheres to the IMI Education & Training Quality Standards as well as to the PharmaTrain Syllabus, Learning Outcomes and Curriculum for Training in Pharmaceutical Medicine.

The following postgraduate courses were offered in 2025:

Diploma/Certificate Course (DAS/CAS) in Pharmaceutical Medicine

The 17th cycle started in September 2023 and ended with the examination in August 2025. The 18th cycle (2025–2027) started in September 2025 with Module 1 of the course.

Fundamentals in Health Economics

This course addresses the role of health-economic thinking in the drug development process. Participants are provided with an understanding of the key principles and methodological concepts of health economic evaluation. This course enables them to assess and appraise published health economic analyses according to guidelines.

Project Management in the Life Sciences Industry

This intensive 6-day course (in two parts) focuses on projects in the life sciences industry and the clinical trial setting ranging from pre-clinical to phase III studies and post-marketing studies. It teaches all the relevant steps and techniques to accurately plan, conduct, and evaluate life sciences projects.

Participants benefit from instructor-led training and group work on real case studies. They work on projects characterized by a high degree of complexity requiring professional management at all stages and levels.



Nikki Liversidge, Monika Graff and Annette Mollet are welcoming the participants to the new course cycle.

Education & Training.

Objectives for the coming years.

The objectives of ECPM are to maintain the high quality of the study program, to implement the latest trends and to retain the leading role in the training of Medicines Development.

The ECPM Diploma Course is recognized by the Swiss Association of Pharmaceutical Medicine (www.sgpm.ch), by the Swiss Medical Association (www.fmh.ch) and the Swiss Association of Pharmaceutical Professionals (www.swapp.ch) to cover the theoretical training and the examination for specialization and board certification. In addition, specific courses are accredited by the Swiss Association of Pharmacists (FPH, www.pharmasuisse.org) for continuing education.

Collaboration with professional associations and our customers from the pharmaceutical industry, academia and regulatory authorities are key. Therefore, our focus remains on strengthening and developing the Master of Advanced Studies to offer the course participants the opportunity to join CPD short courses and acquire credit points, tailored to their needs.

Through the Bologna system it is possible to acquire credit points at other universities. The rule is that at least 50% of the training and the master thesis must be completed at the university where the candidate is enrolled.


The first Master candidate graduated in 2015, with a further 13 candidates completing their degrees between 2018-2025. Several students are in the process of attending master module courses and writing their master thesis.

Besides the collaboration with the partner universities in Europe, ECPM collaborates internationally with partners that offer courses based on the same training syllabus.

Namely the Peking University Clinical Research Institute (PUCRI) at the University of Beijing and the University of California San Francisco to exchange knowledge and enhance training competencies and standards. A number of faculty members teach on all three courses and several students have already switched between the programs due to their changing employment in the global industry.

Education & Training.

ECPM Training Opportunities



ECPM Certificate and Diploma Course (CAS, DAS) in Pharmaceutical Medicine

The ECPM course is a well-established postgraduate education and training program targeted at representatives from the pharmaceutical industry, service industry, academic and government decision- and policy-makers who already have a good understanding of the basics and will benefit from a more in-depth, comprehensive and systematic immersion into modern medical product development, regulation and market introduction.

Course participants are involved in lectures, panel discussions, team-oriented case studies and interactive learning. Participation in the course provides the opportunity to integrate work and education, to discuss with experts face-to-face or online, to gain in-depth knowledge while building an international network, and to put this into perspective with each participant's own career plan.

A faculty network of experts from academia, pharmaceutical and biotechnology companies

and regulatory authorities (including the European Medicines Agency, the Food and Drug Administration, Japanese and Emerging Markets regulatory agencies) carry the teaching responsibility. A successful completion of the course and the final examination provides the title Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine and includes 30 ECTS credits.

Master Course (MAS) in Medicines Development

The Master of Advanced Studies in Medicines Development (MMD) is a postgraduate Master course. This program extends the Diploma course in Pharmaceutical Medicine. CPD short courses that count towards the Master, can be chosen according to the needs and interests of the candidates who need to be able to cope with the challenges of drug development. Training and skills provide the basis to critically assess and improve challenges in the drug development process.

The program is designed as an executive course that can be completed in addition to working full or part-time.

Frontiers in Drug Development Seminars

Integrated into the modules of the Diploma course, ECPM offers one-day “Frontiers in Drug Development” seminars on current trends and hot topics. These seminars are open to the public and are accredited for continuing education by different professional organizations, such as the Swiss Medical Association (FMH).

Examination

The final examination was offered onsite at the University of Basel on August 19 and September 9, 2025.

Multiple choice examination (MCQ):

Out of 84 candidates 74 passed the MCQ examination on August 19, 2025. The questionnaire existed of 120 MC questions which included two types of questions. 70 questions were of the “single best answer” type (one out of five possible answers is correct) and 50 questions of the “multiple true

false” type (each of the four possible answers has to be rated correct or false).

Two questions had to be eliminated due to ambiguity which makes a total of 118 possible points.

Oral/Essay examination:

The oral/essay examination was held on August 19 and September 9. This part of the examination is mandatory to achieve the diploma title (DAS). The oral examination is a discussion based on a scientific paper and the essay examination comprises three one-page summaries on topics covering clinical development, regulatory affairs or safety/pharmacovigilance. Both the MCQ and the Essay examination were performed on an iPad. Overall, 60 out of 63 candidates passed the exam. Three candidates failed the oral/essay in August and no candidate failed in September.

We were able to award 14 CAS, 52 DAS and 11 FMH Specialist titles to our participants during the exams in 2025.



Art intervention at Biozentrum symbolizing the pharma research hub in Basel.

E-learning

To cope with the limited time resources and reduced budgets of specialists working in the health care environment, ECPM has produced three e-learning programs. E-learning modules can be used for different teaching purposes. Firstly, they can be used as a self-learning tool for preparation or repetition of the course material, secondly, they can replace selected face-to-face modules required to achieve the Master in Medicines Development, and thirdly they enable students to collect credits for Continuing Professional Development (CPD):

- Basics in Health Economics (launched 2013)
- Drug Safety and Pharmacovigilance (launched 2014)
- Personalized Healthcare (launched 2015)
- The Pathway of Drug Development (launched 2021)
- A Certificate of Attendance from the University of Basel will be awarded after successful completion of each e-learning program (1 ECTS).
- The chapters comprise short lectures with animated slides and quizzes to check the learning outcomes.

Electronic Learning Platform

We continue to maintain our electronic training platform (initially launched in 2022) containing course documents, videos, books, self-assessments and e-learnings hosted by Cometis.

Education & Training Projects in 2025

- Performed Modules 5 and 6 and thus completed our 17th Diploma Course Cycle with 108 participants (more than 2100 since the initiation of the program)
- Started our 18th Diploma Course Cycle with Module 1 in September
- Awarded 14 CAS, 52 DAS and 11 FMH Specialist titles
- Thomas Szucs published his new book *Gen-Recht in der Schweiz*

- Published a new book chapter 'Educating Future Leaders in Drug Development About AI' in the textbook 'Medical Education in the Age of Digital Transformation'
- Frontiers in Drug Development seminars, "Applying Artificial Intelligence across Drug Discovery and Development", "Small Clinical Trials, Big Opportunities!" and "The Vital Role of Patients in Shaping Drug Development"

Planned Education & Training Projects for 2026

- Delivering Modules 2, 3 and 4 of the 18th course cycle and the interim examinations for CAS, DAS and FMH specialist titles
- Working on several new training and teaching programs, including a course on market access
- Frontiers in Drug Development seminars, in particular "The Next Era of First-in-Human Technologies", Novel Clinical Study Designs: Decentralization, Sustainability, Synthetic Data" and "Advances in Pharmacovigilance: Ensuring Safety of Drugs"
- ECPM representation at the Drug Information Association (DIA) Europe conference in Rotterdam, Switzerland
- Scientific program of the joint annual meeting 2026 of the Swiss Association of Pharmaceutical Physicians (SGPM) and ECPM on "Dementia and Alzheimer's Disease"

PharmaTrain Board

Annette lead the PharmaTrain accreditation committee for DIA Basel.

Undergraduate Teaching at the University of Basel Medical School

1. Szucs TD, Mollet A. Tutorate im Wissenschaftsmonat (WiMo) für Medizinstudenten, 4. / 5. Studienjahr Medizin Master
2. Szucs TD, Mollet A, Interprofessionelles Modul Medikamentenentwicklung. Major Clinical Medicine, 2. Studienjahr Medizin Bachelor.
3. Szucs TD. Interprofessionelles Modul Pharmakogenomik und personalisierte / individualisierte Medizin. Major Clinical Medicine, 2. Studienjahr Medizin Bachelor.
4. Barbier M. Ökonomie und Gesundheit (Vorlesung). Major Clinical Medicine, 1. Studienjahr Medizin Bachelor.
5. Barbier M. Gesundheitsökonomie (Vorlesung), 2. Studienjahr Medizin Master.
6. Schwenkglenks M, Lupatsch JE. Interprofessionelles Modul Finanzierung und Vergütung im Schweizer Gesundheitswesen. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
7. Schwenkglenks M. Interprofessionelles Modul Gesundheitspolitik – Eine Einführung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
8. Szucs TD. Grundlagen und Übersicht. Einführung in die Medikamentenentwicklung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
9. Szucs TD. Phasen 2 und 3 Prüfungen. Einführung in die Medikamentenentwicklung. Major Clinical Medicine, 3. Studienjahr Medizin Bachelor.
10. Schwenkglenks M. Gesundheitsökonomie – Eine Einführung. Part of lecture series Patienten-orientierte Evidenz-basierte Medizin (POEM), 3. Studienjahr Medizin Bachelor.
11. Schwenkglenks M, Salvador D, Barbier M Kleingruppenseminare im Themenblock Körper, Subjekt, Umwelt, 1. Studienjahr Medizin Bachelor.
12. Schwenkglenks M. Funktion und Finanzierung des schweizerischen Gesundheitswesens. Part of lecture series B6: Public Health und Präventivmedizin, Studium Sport, Bewegung und Gesundheit Bachelor.

Undergraduate Teaching at the University of Basel, Faculty of Science

1. Schwenkglenks M. Lectures forming part of Essentials in Drug Development & Clinical Trials.

Undergraduate Teaching at the University of Zurich

1. Szucs TD, Mollet A. Mantelstudium Arzneimittelentwicklung. 2.–4. Studienjahr Medizin Bachelor, Universität Zürich.
2. Szucs TD, Mollet A. BME310 – Research methodology for studies on human health and disease. 3. Studienjahr Biomedicine Master.
3. Szucs TD. BME318 – Clinical Epidemiology and Quantitative Research in Health Care. 3. Studienjahr Biomedicine Master.
4. Szucs TD, Mollet A. BME329 – Developing New Medicines: An Introduction.
5. Szucs TD, 3. Studienjahr Biomedicine Master (responsible PD Dr. Patricia Blank).

Undergraduate Teaching at the University of Bern

1. Schwenkglenks M. Lectures on Health economic evaluation and Health Technology Assessment in Switzerland and Europe. Master Biomedical Engineering.

Postgraduate Teaching at the University of Basel

1. Mollet A, Szucs TD, Schwenkglenks M. Lectures forming part of the ECPM Course in Pharmaceutical Medicine.
2. Schwenkglenks M. Gesundheitsökonomische Modellierung – Hands-on. Course forming part of the Postgraduate Master Program in Public Health.
3. Schwenkglenks M. Basics of Health Economic Evaluation. Lecture forming part of CAS Clinical Research II, Module: Advanced Clinical Trial Management.
4. Barbier M (course organizer and lecturer).. Lambiris M, Lupatsch J, Meier N, Salvador D, Schur N, Stoffel ST 41127 Health Economics, Master and PhD students, Semester course at the Institute of Nursing Sciences.

Postgraduate Teaching at the University of Zurich

1. Schwenkglenks M. Gesundheitsökonomie. Course forming part of the Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.
2. Schwenkglenks M. Gesundheitsökonomische Evaluation. Course forming part of the Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.
3. Szucs TD. Gesundheitsrecht. Course forming part of Postgraduate Master Program in Public Health, Universities Basel, Bern, Zürich.



Diane Jorkasky discussing a case study on safety in early drug development.

Research.

Current Status.

The research group at ECPM has maintained its position as one of the most active health economics groups in Switzerland, in terms of publication activity, project scope, and scale, with about 6 full-time equivalents of scientific staff.

ECPM's research activities started in 2003. Funding is achieved in a balanced way from industry, health insurance providers, governmental and semi-governmental organizations, medical collaborative study groups, and competitive research funding institutions.

We have been and are responsible for the health economic components of various clinical trials and cohort studies, e.g. funded by the European Union and the Swiss State Secretariat for Education, Research and Innovation or the Swiss National Science Foundation. We also cooperate, since 2007, with the Swiss Cancer Institute (formerly Swiss Group for Clinical Cancer Research, SAKK), the leading Swiss collaborative study group in oncology and hematology. We are engaged in exchange and are pursuing cooperation with relevant academic, non-academic and public players in the field of Health Technology Assessment (HTA).

Projects with industrial partners continue to play a relevant role. In cooperation with the

Helsana Group, we have, for the eleventh time, published a report on medication utilization in Switzerland, based on health insurance claims data covering about 15 % of the Swiss population (Helsana Arzneimittelreport). Projects and resulting publications are listed in section Overview of Activities, below.

The strategic development of our research activities profits from fruitful exchange within the Department of Public Health of the Medical Faculty. We pursue and have intensified our cooperation with other health economics groups at the Faculty of Business and Economics and the Swiss Tropical and Public Health Institute, now formalized in the Basel Center for Health Economics. Further cooperations are with the Department of Clinical Epidemiology, and the Basel Pharmacoepidemiology Unit located at the Natural Sciences Faculty, and with the Surgical Outcomes Research Center at Basel University Hospital.

Research is done in the following therapeutic areas: Oncology and hematology, cardiovascular disease and heart failure, neurology, sepsis and other infectious diseases, geriatrics, including pharmacotherapy optimization in the elderly and palliative care, and patient safety.

Key Areas of Expertise

1. [Economic Evaluation](#) of clinical interventions (trial-based and decision-analytic model-based)
2. [Economic Evaluation](#) of Healthcare Programmes, [including Implementation Science](#)
3. [Value-Based Healthcare \(VBHC\)](#)
4. [Health Technology Assessment \(HTA\)](#)
5. Budget Impact Analysis (BIA)
6. Analysis of [Real World Data \(RWD\)](#), most importantly health insurance claims data
7. Systematic reviews and meta-analyses
8. [Behavioral health economics](#)
9. [Environmental health economics](#)
10. [Health Preferences Research](#)
11. Health Services and Outcomes Research
12. [Valuation of Patient Outcomes](#), such as Quality of Life
13. Biostatistics, clinical trial and epidemiological study designs
14. Surveys

Research.

Objectives for the coming years.

The situation and achievements of ECPM in 2025 reflect the continued, successful development of a small research unit. In the coming years, we will seek to maintain a sensible balance of competitively (EU, potentially SNSF), publicly and privately funded research projects. As third-party funding of Health Technology Assessment-related and health economic evaluation-related research remains structurally uncertain, we also need to gain substantially more long-term university funding for our research group to ensure sustainability.

In 2025, we pursued the development of the HEF strategy and, mediated through the HEF, the

anchoring of health economics and health services research in the Medical Faculty. We plan to further contribute to shaping the research strategy and overall structural development of the Department of Public Health. From a scientific perspective, we also plan to further extend our activities in trial-based cost-effectiveness analyses (e.g. addressing methodological issues around international trials, approaches to missing values), evidence synthesis methods for health economic evaluation results, causal inference methods applied to real-world data (e.g. health insurance data), health services research and behavioral economics. Decision-analytic modelling remains a strong cornerstone.



Presentation and lively discussion of results elaborated in case study group discussions.

Research.

Overview of activities.

Sources of incoming funding 2025



Incoming funding 2025, KCHF 812

Federal Office of Public Health	8%
Foundation	16%
Industry	6%
Insurance companies	15%
Other	6%
Other Hospitals	8%
Swiss National Science Foundation, Innosuisse	30%
University core funding	10%
Total	CHF 812 611 CHF 100%

Local academic collaborations

- Prof. Stefan Felder, Health Economics, Faculty of Business and Economics, University of Basel
- Prof. Kaspar Wyss, Swiss Centre for International Health (SCIH), and Prof. Günther Fink, Household Economics and Health Systems Research, Swiss Tropical and Public Health Institute Basel
- Prof. Michael Simon and Prof. Sabina De Geest, Institute of Nursing Science, University of Basel
- Prof. Niklaus Labhardt, Prof. Matthias Briel and Clinical Study Center, Department of Clinical Research (DKF), University of Basel and University Hospital Basel
- Prof. Christoph Meier, Pharmacoepidemiology Unit, University of Basel, and Hospital Pharmacy Basel, University Hospital Basel
- Surgical Outcomes Research Center (SORC) at University Hospital Basel
- Clinical units at University Hospital Basel

Collaborations with national and international academic and public entities

- Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- University Hospital Berne
- Institute of Social and Preventive Medicine, University of Bern
- Swiss Cancer Institute (formerly Swiss Group for Clinical Cancer Research, SAKK)
- University Children's Hospital Zurich
- Federal Office of Public Health

Collaborations with private entities

- Health Insurance companies
- Pharmaceutical companies

Research.

Upcoming Projects: outlook 2026.

New	
Title:	Patient and professional views on cancer trials
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	Assess knowledge, attitudes, and experiences with clinical cancer trials among patients and oncology professionals at Kantonsspital Luzern.
Start date:	05/2026
Partner(s):	Kantonsspital Luzern
Output:	Pending
Source of funding:	Krebsliga Zentralschweiz



Thomas Szucs introducing the students to the different health care systems.

Research.

New Projects (started in 2025).

New

Title:	Health economic analyses and evaluation of the Swiss Sepsis Program
Project lead & contributors:	STS, DS, MS
Hypothesis / Objectives:	Estimating the economic burden of sepsis in Switzerland
Start date:	01/2025
Partner(s):	Universitäts-Kinderspital Zürich
Output:	Pending
Source of funding:	Swiss Sepsis Program, Universitäts-Kinderspital Zürich

New

Title:	Economic analysis alongside SAKK 96/12 trial
Project lead & contributors:	EA ,DS, STS, MS,
Hypothesis / Objectives:	Estimates the cost-effectiveness of reducing the frequency of denosumab administration.
Start date:	05/2025
Partner(s):	Swiss Cancer Institute (SCI)
Output:	Health economic evaluation ongoing Abstract submission for ESMO planned for 13 May 2026.
Source of funding:	Cancer Research Switzerland

New

Title:	Implicit bias in oncology
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	Examines implicit biases in oncologists' treatment decisions through a web-based factorial experiment. Specifically, it explores whether the patient's sex affects the likelihood of oncologists recommending curative treatment.
Start date:	08/2025
Partner(s):	Berne University Hospital
Output:	Pending
Source of funding:	Philas Foundation

New

Title:	Cost-effectiveness and reimbursement of anti-CGRP drugs for migraine in Switzerland
Project lead & contributors:	MA, MB, MS, ML
Hypothesis / Objectives:	The cost-effectiveness and budget impact of reducing the barriers to reimbursement of anti-CGRP drugs in Switzerland to people with episodic and chronic migraines. A simulation model of the care pathway is coupled with a burden model and a cost model to evaluate how more generous reimbursement policy would impact burden and costs.
Start date:	01.10.2025
Partner(s):	Industry
Output:	Report, model, and manuscript for peer-reviewed publication.
Source of funding:	Industry

New

Title:	Pharmacoeconomic modelling of Ginkgo biloba for cognitive impairment
Project lead & contributors:	NSch, ML, MS
Hypothesis / Objectives:	Pharmacoeconomic modelling of dementia treatment with Ginkgo biloba from the perspective of the Swiss statutory health insurance system and from the Swiss societal perspective.
Start date:	01/2026
Partner(s):	Industry
Output:	Pending
Source of funding:	Industry

Research.

Ongoing projects.

Ongoing

Title:	The LYMPH Trial – Surgical versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema: A Pragmatic, Randomized, Multicenter Superiority Trial
Project lead & contributors:	JL, NSch, MS
Hypothesis / Objectives:	Primary Objective The primary objective of this trial is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, upper limb, questionnaire) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE). Secondary Objectives Secondary objectives will compare lymphatic surgery versus conservative treatment only in terms of further QoL aspects, arm volume, safety, burden on patients and pain.
Start date:	07/2023
Partner(s):	PD Dr. med. Elisabeth Artemis Kappos (USB)
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Economic analysis alongside PFOA II trial
Project lead & contributors:	DS, MS
Hypothesis / Objectives:	PFOA II is a Phase II clinical trial wherein a nasal cartilage graft is harvested from a patient with knee osteoarthritis and grown to sufficient size in a tissue laboratory, and then transplanted to repair large defects in the patella of the same patient. The comparator is intra-articular joint injection of platelet-rich plasma. A cost-utility analysis will be performed, and it is hypothesized that the intervention is cost-effective in the long term, considering the potential cost savings for avoiding knee replacement surgery, rehabilitation, complications, as well as improving function, reducing pain, and higher quality of life.
Start date:	09/2023
Partner(s):	USB
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Cost data of patients dying in the hospital: does Palliative Care matter?
Project lead & contributors:	MS, MB
Hypothesis / Objectives:	The retrospective study's primary objective is calculate hospital costs of patients who died at University Hospital Bern (Inselspital) between 2016–2020. The overall hospital costs of patients who received palliative care are compared with the costs of those who received usual care (UC). Additionally, the study assesses the role of different types of palliative care patients, and of different cost types. ECPM supports the partner at University Hospital Bern with expertise in cost analysis and related aspects.
Start date:	09/2022
Partner(s):	University Centre for Palliative Care, University Hospital Bern
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Spearhead: Fighting Antimicrobial resistance through rapid digital pandemic response
Project lead & contributors:	ML, JL, YA, MS
Hypothesis / Objectives:	To contribute to optimised practices in managing antimicrobial resistance (AMR) that may easily be harnessed to address future emerging infections. ECPM is responsible for developing a conceptual model including the reasons and consequences of AMR and for performing the cost-effectiveness of a novel diagnostic which substantially reduces the time to results of an antibiotic susceptibility test, compared with currently used technologies.
Start date:	01/2022
Partner(s):	Consortium of 8 public and 4 private Swiss institutions
Output:	Pending
Source of funding:	Innosuisse

Ongoing

Title:	DepRescribing inapprOpriate Proton Pump InibiTors trial
Project lead & contributors:	MB, MS
Hypothesis / Objectives:	To evaluate the cost-effectiveness of the trial intervention through health economic analyses.
Start date:	09/2022
Partner(s):	BIHAM (Institute of Primary Health Care) team in Bern
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	MultiSCRIPT –Treatment Optimization in Multiple Sclerosis
Project lead & contributors:	MS, ML
Hypothesis / Objectives:	This study investigates how intensive monitoring of biomarkers can improve patient-relevant outcomes as well as the care of MS patients.
Start date:	11/2022
Partner(s):	Universitätsspital Basel, Departement Klinische Forschung, Inselspital, L'Ente Ospedaliero Cantonale
Output:	Pending
Source of funding:	Schweizerische Nationalfonds Investigator initiated clinical trials

Ongoing

Title:	Pre- versus sub-pectoral implant-based breast reconstruction after nipple-sparing mastectomy (OPBC-02 PREPEC): A pragmatic, multicenter, randomized, superiority trial
Project lead & contributors:	JL, MWL, NSch, MS
Hypothesis / Objectives:	ECPM: establish health economic properties of the compared surgical techniques
Start date:	07/2019
Partner(s):	Prof. Walter Paul Weber, Klinik für Allgemeinchirurgie, Universitätsspital Basel
Output:	Pending
Source of funding:	Swiss National Science Foundation

Ongoing

Title:	Drug utilization reports based on Swiss health insurance claims data
Project lead & contributors:	NSch, JL, STS, MS
Hypothesis / Objectives:	Analysis of drug use in Switzerland and related medical and economic aspects, based on Swiss health insurance data
Start date:	09/2013
Partner(s):	Helsana
Output:	https://reports.helsana.ch/arzneimittel2025/
Source of funding:	Health insurance provider

Ongoing

Title:	Evaluation project alongside a project on falls prevention
Project lead & contributors:	NSch, YA, MS
Hypothesis / Objectives:	Formative, outcome and impact evaluation of project: «Sturzprävention in der Gesundheitsversorgung – Überführung in die Regelversorgung (StoppSturz)»
Start date:	03/2019
Partner(s):	Swiss Tropical and Public Health Institute
Output:	https://gesundheitsfoerderung.ch/node/8980 Factsheet: https://gesundheitsfoerderung.ch/sites/default/files/2024-03/FB_100_Eval_StoppSturz_de_web.pdf
Source of funding:	Health Promotion Switzerland

Ongoing

Title:	Evaluation project alongside a prevention project on somatoform disorders
Project lead & contributors:	NSch, DS, MS
Hypothesis / Objectives:	Formative, outcome and impact evaluation of project: «Prävention psychosozialer Belastungsfolgen in der Somatik: ein Modellprojekt zur kollaborativen Versorgung (SomPsyNet)»
Start date:	03/2019
Partner(s):	University Hospital Basel, Swiss Tropical and Public Health Institute
Output:	Internal reports; https://pubmed.ncbi.nlm.nih.gov/35592378/ https://doi.org/10.1186/s12888-021-03353-5 will present results of first followup(6 months) at SwissTPH on 27 April 2026
Source of funding:	Health Promotion Switzerland

Ongoing

Title:	QoL versus LoL
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	Investigate whether patients with gastric cancer change their preferences for quality of life (QoL) vs length of life (LoL) during their treatment
Start date:	01/2024
Partner(s):	Dr Mickael Chaevallay (HUG)
Output:	Pending
Source of funding:	Krebsliga Schweiz

Ongoing

Title:	Enhancing palliative Care in ICU (EPIC)
Project lead & contributors:	MS, MB, EA
Hypothesis / Objectives:	The EPIC project implements • a harmonized palliative care practice model for the ICU (the EPIC model) • a multicentre randomised clinical trial to document the effectiveness of the EPIC model substudies to strengthen and refine the EPIC model for sustainability • a social science and humanities approach to develop ethical guidelines for the European civic society. • Within EPIC, ECPM is responsible for the health economic part of the clinical trial
Start date:	01/2024
Partner(s):	Charité Universitätsmedizin Berlin, Germany; partners of the EPIC consortium
Output:	Pending
Source of funding:	EU HORIZON Europe: European Union / Swiss State Secretariat for Education, Research and Innovation

Ongoing

Title:	Accompanying research Réseau de l'Arc
Project lead & contributors:	MS, MB, SM
Hypothesis / Objectives:	The Basel Center for Health Economics (BCHE), with its member organization ECPM, and the Swiss Tropical and Public Health Institute (Swiss TPH), will be studying the integrated care model Réseau de l'Arc over several years. The aim is to assess its impact on various qualitative, quantitative and economic aspects of healthcare, including efficiency and the development of care costs.
Start date:	03/2024
Partner(s):	Faculty of Business and Economics, Swiss TPH, Réseau de l'Arc, Swiss Medical Network, Visana, Canton Bern
Output:	Pending
Source of funding:	Integrated care organization

Ongoing

Title:	CIBO-Surg
Project lead & contributors:	DS, STS, MS
Hypothesis / Objectives:	CIBOSurg project is a quality improvement and implementation research wherein a structured recording of intraoperative complications is performed and discuss them in the team at the end of the operation in the sign-out (3rd part of the WHO Safe Surgery Checklist). The clinical tool to be used is called ClassIntra®: the first prospectively validated classification for standardized assessment intraoperative adverse events. This intervention is expected to improve surgical outcomes and reduce preventable post-surgical events. This is expected to reduce overall health system costs
Start date:	03/2024
Partner(s):	Prof Dell-Kuster, USB
Output:	Pending
Source of funding:	Stiftung Anästhesiologie und Intensivmedizin

Ongoing

Title:	HE in cancer
Project lead & contributors:	MB, Oliver Gautschi, Patrick Kälin
Hypothesis / Objectives:	An ICER for high priced drugs in oncology
Start date:	05/2025
Partner(s):	Medical Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
Output:	Pending
Source of funding:	Stiftung FAG (Dr. Roland Entschel Fond)

Ongoing

Title:	MSD PAH
Project lead & contributors:	MS, STS
Hypothesis / Objectives:	Estimate the annual direct and indirect costs of pulmonary arterial hypertension (PAH) in Switzerland, from a societal perspective.
Start date:	07/2023
Partner(s):	University of Zurich
Output:	Pending
Source of funding:	MSD

Research.

Completed projects.

Completed	
Title:	Herding (sex-driven)
Project lead & contributors:	STS, MS
Hypothesis / Objectives:	Examines the ingroup bias among female primary care physicians in a web-based experiment. Specifically, it investigates whether female primary care physicians are more likely to follow to incorrect prescription recommendations from a female specialist compared to a male specialist.
Start date:	08/2025
Partner(s):	Berne University Hospital
Output:	https://doi.org/10.1186/s12916-026-04716-z
Source of funding:	Freiwillige Akademische Gesellschaft Basel and Berne University Hospital
Completed	
Title:	Quantifying the future of osteoporosis in Switzerland
Project lead & contributors:	NSch, MS
Hypothesis / Objectives:	The aim of the project is to assess future epidemiological and economic consequences of osteoporosis in the Swiss population to predict the situation from 2020 to 2040 based on different demographic scenarios. Strategy comparisons are planned to demonstrate the effect on the treatment gap in situations where full uptake of interventions would be achieved vs. no uptake of any interventions.
Start date:	12/2023
Partner(s):	Prof. Dr. med. Kurt Lippuner, Universitätsklinik für Osteoporose, Inselspital, Bern
Output:	Pending
Source of funding:	Research Fund Junior Researchers, Universität Basel
Completed	
Title:	Cannabis
Project lead & contributors:	STS
Hypothesis / Objectives:	Combine data from cannabis pilot studies to analyse the impact of participating in them on health and consumption behaviour
Start date:	11/2023
Partner(s):	BAG
Output:	Internal report
Source of funding:	BAG
Completed	
Title:	Trastuzumab
Project lead & contributors:	DS, MS
Hypothesis / Objectives:	HTA aiming to assess the clinical efficacy, safety, costs, cost-effectiveness, budget impact, and ethical, legal, social and organizational issues related to ≤6 months of neoadjuvant or adjuvant treatment with trastuzumab compared to 12 months of treatment, and related to ≤6 months of combination treatment with neoadjuvant or adjuvant trastuzumab and pertuzumab compared to 12 months of treatment in women with HER2-positive early breast cancer.
Start date:	05/2023
Partner(s):	University of Zürich, USZ, FOPH
Output:	Pending – awaiting publication
Source of funding:	Swiss Federal Office of Public

Completed

Title:	PsyYoung economic analysis
Project lead & contributors:	DS, NSch, MS
Hypothesis / Objectives:	Estimate the cost in Switzerland of facilitating access to care for young people at risk for psychotic disorders.
Start date:	01/2022
Partner(s):	Prof. Dr. Christina Andreou, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
Output:	Final report submitted to CHUV, publication depending on publication of clinical results
Source of funding:	CHUV

Completed

Title:	Value-based Health Care Data analysis on lung cancer costs and patient-reported outcomes
Project lead & contributors:	MB, ML, MS
Hypothesis / Objectives:	Develop an algorithm to merge administrative datasets from the University of Basel Hospital covering services and billings with PROMs/CROMs for lung cancer patients treated at the Hospital; analyze the linked datasets to identify treatment patterns and relate these to patient outcomes and costs toward optimal care pathways.
Start date:	10/2021
Partner(s):	University of Basel Hospital, Industry
Output:	Pending
Source of funding:	University of Basel Hospital, Industry

Activities of the ECPM collaborators in 2025.

Publications, Scientific Presentations, Evaluation of Research Projects and Thesis Supervision.

El Saadany, Tämer ... Lupatsch, Judith (2) ... Barbier, Michaela (4) ... Schwenkglenks, Matthias (6) ... Von Moos, Roger

A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRASG12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland

2025, Schweizerische Medizinische Wochenschrift, 155

10.57187/s.3777, journal contribution, (F.1.1)

Barbier, Michaela Carla ... Lambiris, Mark (3) ... Schwenkglenks, Matthias

Contributing to a value-based health care framework for lung cancer patients in Switzerland – A methodological approach to merge routinely collected hospital data

2025, PLOS ONE, 20

10.1371/journal.pone.0327814, journal contribution, (F.1.1)

Meier, Niklaus Roar

Cost-effectiveness and individualized treatment rules in treatments for haemophilia

2025, 181

doctoral thesis, (F.3.6)

Montilla, Precious Juzenda ... Salvador, Dante (11) ... Añonuevo, John

Cost-utility analysis of empagliflozin for heart failure in the Philippines

2025, Journal of Medical Economics, 28, 157–167

10.1080/13696998.2024.2447180, journal contribution, (F.1.1)

Stoffel, Sandro Tiziano ... Buyse, Sophie

Current Sustainability Policies in Gastrointestinal Endoscopy: Insights from a Survey of Swiss Endoscopists

2025, Green Health, 1, 22

10.3390/greenhealth1030022, journal contribution, (F.1.1)

Barbier, Michaela ... Schwenkglenks, Matthias

Enhancing Palliative Care in Intensive Care Units (EPIC) Trial -Design of the Health Economic Substudy

2025, ISPOR Europe 2025

10.1016/j.jval.2025.09.795, conference poster (not in proceedings), (F.1.2)

Stoffel, Sandro T ... Schwenkglenks, Matthias

Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional survey

2025, BMJ Open, 15, e090401

10.1136/bmjopen-2024-090401, journal contribution, (F.1.1)

Stoffel, Sandro T. ... Schwenkglenks, Matthias

Estimating the indirect costs associated with adenocarcinoma or squamous cell carcinoma of the oesophagus in Switzerland: evidence from a cross-sectional survey

2025, BMJ Open, 15

10.1136/bmjopen-2024-090401, journal article, (F.1.1)

Schur, Nadine ... Lupatsch, Judith (2) ... Schwenkglenks, Matthias

Helsana-Arzneimittelreport 2025

2025, 112

report, (F.4.1)

Stoffel, Sandro T. ... Schinkel, Helga

Identification of Cost-Relevant Factors in the Production of a Triterpenoid Saponin in Hydroponically Grown Soapwort: A Case Study

2025, Horticulturae, 11, 353

10.3390/horticulturae11040353, journal contribution, (F.1.1)

Aebersold, Helena ... Szucs, Thomas (21) ... Schwenkglenks, Matthias

Impact of atrial fibrillation on productivity in working-age patients: an analysis of Swiss-AF prospective cohort study data

2025, Schweizerische Medizinische Wochenschrift, 155

10.57187/s.3669, journal article, (F.1.1)

Yfantidou, Ioanna ... Stoffel, Sandro

Mapping the Gaze: Comparing the Effectiveness of Bowel-Cancer Screening Advertisements

2025, Information (Switzerland), 16, 935

10.3390/info16110935, journal contribution, (F.1.1)

Meier, Niklaus ... Schwenkglenks, Matthias

Systematic review of cost-effectiveness modelling studies for haemophilia

2025, Journal of Medical Economics, 28, 89-104

10.1080/13696998.2024.2444157, journal contribution, (F.1.1)

Meier, Niklaus ... Schwenkglenks, Matthias

Systematic review of cost-effectiveness modelling studies for haemophilia

2025, Journal of Medical Economics, 28, 89–104

10.1080/13696998.2024.2444157, journal contribution, (F.3.7)

Szucs, Thomas

Tattoo ink between beauty and risk: regulation in Switzerland, the EU and the USA

2025, 138–140

journal article, (F.1.3)

Stoffel, Sandro Tiziano ... Von Wagner, Christian

The impact of dynamic social norms messages on motivation to participate in organized colorectal cancer-screening programmes: evidence from an online experiment

2025, Frontiers in Behavioral Economics, 4

10.3389/frbhe.2025.1566172, journal contribution, (F.1.1)

- Stoffel, Sandro Tiziano ... von Wagner, Christian
The impact of temporal framing of breast cancer risk on perceptions of and motivations to engage with information about early diagnosis: Evidence from an online experiment
 2025, PLOS ONE, 20, e0320245
 10.1371/journal.pone.0320245, journal contribution, (F.1.1)
-
- Ali, Nazia Binte ... Lambiris, Mark (5) ... Sudfeld, Christopher R.
Acute Undernutrition and Child Development in Low- and Middle-Income Countries: A Meta-analysis
 2025, Nutrition Reviews
 10.1093/nutrit/nuaf178, journal contribution, (F.1.1)
-
- Bollinger, Anna ... Schwenkglenks, Matthias (7) ... Allemann, Samuel S.
Association of Pharmacogenotyping and Patient-Reported Outcomes in Chronic Pain Management
 2025, Health Services Insights, 18
 10.1177/11786329251356560, journal contribution, (F.1.1)
-
- Añonuevo, John ... Salvador, Dante (8) ... Montilla, Precious Juzenda
Cost-of-illness of heart failure with preserved and reduced ejection fraction in the Philippines
 2025, Journal of Medical Economics, 28, 814-822
 10.1080/13696998.2025.2504269, journal contribution, (F.3.7)
-
- Schulthess-Lisibach, Angela Edith ... Barbier, Michaela (17) ... Vallejo-Yagüe, Enriqueta
DepRescribing inappropiate Proton Pump Inhibitors (DROPIT): study protocol of a cluster-randomised controlled trial in Swiss primary care
 2025, BMJ Open, 15, e094495
 10.1136/bmjopen-2024-094495, journal contribution, (F.1.1)
-
- Weir, Kristie Rebecca ... Barbier, Michaela (13) ... Inauen, Jennifer
Development of a deprescribing intervention for proton pump inhibitors in primary care: A co-design approach with general practitioners and patients
 2025, Basic and Clinical Pharmacology and Toxicology
 10.1111/bcpt.70091, journal article, (F.1.1)
-
- Kerrison, Robert S ... Stoffel, Sandro (3) ... von Wagner, Christian
Effectiveness of behavior change techniques to address barriers to follow-up colonoscopy: results from an online survey and randomized factorial experiment
 2025, Annals of Behavioral Medicine, 59
 10.1093/abm/kaae083, journal contribution, (F.1.1)
-
- Moschovitis, Giorgio ... Schwenkglenks, Matthias (17) ... Krisai, Philipp
External Validation of the REACT-HF Score for Predicting Heart Failure in Patients With Atrial Fibrillation
 2025, Journal of the American Heart Association, 14
 10.1161/jaha.125.043058, journal contribution, (F.1.1)
-

- Perumal, Nandita ... Lambiris, Mark (4) ... Sudfeld, Christopher R.
Human capital and lifetime income gains of scaling-up small-quantity lipid nutrient supplements among children under 2 years: A modelling analysis
 2025, PLOS Global Public Health, 5, e0004388
 10.1371/journal.pgph.0004388, journal contribution, (F.3.7)
-
- Stoffel, Sandro T. ... Schwenkglenks, Matthias (5) ... Schinkel, Helga
Identification of Cost-Relevant Factors in the Production of a Triterpenoid Saponin in Hydroponically Grown Soapwort: A Case Study
 2025, Horticulturae, 11, 353
 10.3390/horticulturae11040353, journal contribution, (F.3.7)
-
- Efthimiou, Orestis ... Schwenkglenks, Matthias (7) ... White, Ian R.
Measuring the Performance of Survival Models to Personalize Treatment Choices
 2025, Statistics in Medicine, 44
 10.1002/sim.70050, journal contribution, (F.3.7)
-
- Harkare, Harsh Vivek ... Antillon, Marina (2) ... Tediosi, Fabrizio
Modelling the health and cost implications of expanded access to HIV, HCV and sexually transmitted infection testing in Switzerland
 2025, Schweizerische Medizinische Wochenschrift, 155
 10.57187/s.4581, journal article, (F.1.1)
-
- Singhal, Taru ... Schwenkglenks, Matthias (5) ... Vounatsou, Penelope
Mortality atlas of the main causes of death for the elderly population (≥ 75 years) in Switzerland during 2010–2020
 2025, Schweizerische Medizinische Wochenschrift, 155, 3433
 10.57187/s.3433, journal contribution, (F.3.7)
-
- Kappos, Elisabeth A ... Schwenkglenks, Matthias (51) ... Weber, Walter
The LYMPH trial: comparing microsurgical with conservative treatment for chronic breast cancer-associated lymphoedema – study protocol of a pragmatic randomised international multicentre superiority trial
 2025, BMJ Open, 15
 10.1136/bmjopen-2024-090662, journal article, (F.1.1)
-
- Hagemann, Monika ... Schwenkglenks, Matthias (3) ... Maessen, Maud
Treatment goals indicate palliative care hospital costs: a longitudinal economic study
 2025, Schweizerische Medizinische Wochenschrift, 155, 4132
 10.57187/s.4132, journal contribution, (F.3.7)
-
- Grimani, Aikaterini ... Stoffel, Sandro T. (2) ... Vlaev, Ivo
Using an inferior decoy alternative to nudge COVID-19 vaccination
 2025, Scientific Reports, 15
 10.1038/s41598-024-84853-8, journal contribution, (F.1.1)
-

Scientific Presentations to External Audiences

Presenter (name, function)	Presentation title	Event (title, location)	Date
Szucs TD, Director	Longevity Day	Vortrag LUX, Zürich	15.01.25
Szucs TD, Director	ECPM 2023–2025 (Modul 5)	Uni Basel	03.02–06.02.2025
Szucs TD, Director	Von der Idee zum Projekt	Vorlesung Universität Basel	17.02.25
Szucs TD, Director	Gesundheitsrecht - Grundlagen Recht - I	Vorlesung Alterszentrum Hottingen	03.03.25
Szucs TD, Director	Gesundheitsrecht - Grundlagen Recht - II	Vorlesung Alterszentrum Hottingen	03.03.25
Szucs TD, Director	Gesundheitsrecht - Grundlagen Gesundheitsrecht - I	Vorlesung Alterszentrum Hottingen	03.03.25
Szucs TD, Director	Mantelstudium FS 2025 - Grundlagen / Einführung in das Recht	Vorlesung UHZ	04.03.25
Szucs TD, Director	Gesundheitsrecht - Humanforschungsrecht	Vorlesung Alterszentrum Hottingen	04.03.25
Szucs TD, Director	Gesundheitsrecht - Arzneimittelrecht	Vorlesung UHZ	04.03.25
Szucs TD, Director	Gesundheitsrecht - Datenrecht	Vorlesung Alterszentrum Hottingen	05.03.25
Szucs TD, Director	Gesundheitsrecht - Medizinprodukterecht	Vorlesung Alterszentrum Hottingen	05.03.25
Szucs TD, Director	Gesundheitsrecht - Gen-Recht	Vorlesung Alterszentrum Hottingen	05.03.25
Szucs TD, Director	Gesundheitsrecht - Kursevaluation	Vorlesung Alterszentrum Hottingen	05.03.25
Szucs TD, Director	Mantelstudium FS 2025 - Einführung in die Medikamenten-Entwicklung / Einführung in die Pharmakologie Teil I	Vorlesung UHZ	11.03.25
Szucs TD, Director	Vorlesung - Diagnosis (BME318)	Vorlesung UHZ	17.03.25
Szucs TD, Director	Mantelstudium FS 2025 - Arztrecht	Vorlesung UHZ	25.03.25
Szucs TD, Director	1 Einführung in die Grundlagen der molekularen Genetik (2)	Vorlesung Alterszentrum Hottingen	31.03.25
Szucs TD, Director	Prognosis (BME318)	Vorlesung UZH	31.03.35

Szucs TD, Director	5 Beurteilung der personalisierten Medizin aus klinischer und gesundheitsökonomischer Sicht	Vorlesung Alterszentrum Hottingen	01.04.25
Szucs TD, Director	6 Nutzen der personalisierten Medizin für primäre Prävention und Screening	Vorlesung Alterszentrum Hottingen	01.04.25
Szucs TD, Director	7 Ethischer, sozialer und rechtlicher Rahmen der personalisierten Medizin	Vorlesung Alterszentrum Hottingen	01.04.25
Szucs TD, Director	Bm329 Intro and Crashcourse Pharma I KOL G212	Vorlesung UZH	04.04.25
Szucs TD, Director	Prämien und Leistungen – die Sicht eines Krankenversicherers (Payor)	Vorlesung HSG	07.04.25
Szucs TD, Director	Mantelstudium FS 2025 - Genrecht	Vorlesung UZH	08.04.25
Szucs TD, Director	Mantelstudium Balgrist Schmerzgenetik	Vorlesung Balgrist	08.04.25
Szucs TD, Director	Bme329 Clin Dev 1–3 & Why do trials fail KOL H 309	Vorlesung UZH	08.04.25
Szucs TD, Director	Mantelstudium FS 2025 – Versicherungsrecht	Vorlesung UZH	15.04.25
Szucs TD, Director	Bme329 Pharma II KOL G 212	Vorlesung UZH	16.04.25
Szucs TD, Director	BME 329 Biostatistical and epidemiological concepts KOL G 212	Vorlesung UZH	16.04.25
Szucs TD, Director	Bme329 PEC, IP Law, Fundamentals Drug Safety and pharmacovigilance KOLH-309	Vorlesung UZH	17.04.25
Szucs TD, Director	Mantelstudium FS 2025 - Phase 1 Prüfungen / Einführung in die Pharmakologie Teil 2	Vorlesung UZH	29.04.25
Szucs TD, Director	Mantelstudium FS 2025 - Informationsrecht und Datenschutz	Vorlesung UZH	06.05.25
Szucs TD, Director	Bme 329 Student presentations KOL H309	Vorlesung UZH	06.05.25
Szucs TD, Director	Mantelstudium FS 2025 - Öffentliches Gesundheitsrecht	Vorlesung UZH	13.05.25
Szucs TD, Director	Health Economics and Pharmacoeconomics	Vortrag ECPM Basel	24.06.25
Szucs TD, Director	Capital Markets and? Drug Development	Vorlesung ECPM	25.06.25
Szucs TD, Director	Walking the thin Line of the Label	Vortrag ECPM Basel	26.06.25

Szucs TD, Director	Forschung und Innovation: Genrecht, Humanforschung	Vortrag MERH Veranstaltung / hmo - Hotel Zürichberg	12.09.25
Szucs TD, Director	Mantelstudium HS 2025 - Grundlagen / Einführung in das Recht	Vorlesung UZH	23.09.25
Szucs TD, Director	Bme 310 epidemiologic study designs kol h309	Vorlesung UZH	24.09.25
Szucs TD, Director	Def Block -BME310 - Vorlesung im strirchel "How to write an Abstract"	Vorlesung UZH	25.09.25
Szucs TD, Director	Principles of premarketing safety and pharmacovigilance ccdrs	Vorlesung Uni Peking (CCDRS)	27.09.25
Szucs TD, Director	Mantelstudium HS 2025 - Arztrecht	Vorlesung UZH	30.09.25
Szucs TD, Director	Vorlesung dev of medicines bme310 und law kol h309	Vorlesung	30.09.25
Szucs TD, Director	Mantelstudium HS 2025 (Teil von Ivan Tomka)	Vorlesung UZH	14.10.25
Szucs TD, Director	Mantelstudium HS 2025 - Versicherungsrecht (08.00 - 10.00 Uhr Ronald Walshe)	Vorlesung UZH	21.10.25
Szucs TD, Director	Mantelstudium HS 2025 - Genrecht	Vorlesung UZH	04.11.25
Szucs TD, Director	Mantelstudium HS 2025 - Informationsrecht und Datenschutz	Vorlesung UZH	11.11.25
M Schwenkglens Head of Research	Kosten und klinischer Benefit in der Onkologie, St. Galler Fortbildung klinische Onkologie 2025	St. Gallen	07.02.25
M Schwenkglens Head of Research	Kosten-Nutzen-Betrachtungen neuer Therapien in der Onkologie, Symposium der Pharmazeutischen Gesellschaft Basel	Basel	20.05.25
M Schwenkglens Head of Research	Cost-effectiveness: how to assess and who is responsible?, SAMO Interdisciplinary Workshop on Choosing Wisely In Oncology, Lucerne	Lucerne	13.09.25

Evaluation of Research Projects and Publications (peer review)

Annette Mollet

- Member of working group to update the PharmaTrain syllabus, chairing the Regulatory group and auditor for PharmaTrain courses
- Organising committee of the Annual Symposium in Pharmaceutical Medicine: “Antimicrobial Resistance”, Florhof Zurich, November 26, 2025
- Peer reviewer for the Journal of Frontiers in Medicine

Matthias Schwenkglens is a member of the Editorial Board of Pharmacoeconomics. He is a reviewer for multiple other clinical and health economic journals.

PhD Theses Supervised by the ECPM Collaborators in 2025

Tabea Frei, Music as an Evidence-Based Intervention: Systematic Investigations of Its Effects in Children with Autism Spectrum Disorder and Individuals with Chronic Pain (PhD thesis in cooperation with UFL – Private University in the Principality of Liechtenstein). Supervised by Thomas Szucs (primary advisor).

Flurina Meier, Predictors of health care utilization and costs as well as influence of the COVID-19 lockdown on loneliness and social isolation in community-dwelling elderly persons (PhD thesis in cooperation with ZHAW). Supervised by Nicole Probst (primary advisor) and Matthias Schwenkglens (secondary advisor).

Niklaus Meier, Cost-effectiveness analyses of medical interventions including gene therapies for haemophilia (PhD thesis in cooperation with Berner Fachhochschule). Supervised by Matthias Schwenkglens (primary advisor).

Kimón Papadopoulos, Reaching Conceptual Equivalence on the Concept of Public Trust in Electronic Health Records (EHRs) on a National Level in a Multi-National European Context working title; PhD thesis at University of Zürich. Supervised by Felix Gille (primary advisor), Viktor von Wyl (responsible faculty member), Matthias Schwenkglens (further faculty member).

Andri Signorell, Parkinson in Switzerland – Prevalence, Care, Risk-Factors (PhD thesis in cooperation with Helsana). Supervised by Matthias Schwenkglens (primary advisor).

Elia Antonini, WORKING TITLE: Within-trial cost-effectiveness analyses: dosing frequency of denosumab (SAKK 96/12 trial) and palliative care in intensive medicine (EPIC trial). Supervised by Matthias Schwenkglens (primary advisor).

Master Theses: MD

Simon Bamert, Robotische Fluoroskopie. Supervised by Norbert Suhm (advisor), Matthias Schwenkglens (co-advisor).

Master Theses: MBA, MMD and MPH

Sahej Verma, “Economics of the CDMO industry: case study of Lonza AG in Visp”. Supervised by Annette Mollet and Thomas Szucs.

Imprint

Published by:


University of Basel
ECPM
Institute of
Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

Design Concept and Layout:
atelier w, Basel

Photography:
Page 3, 6:
© Ursula Sprecher, Basel

Page 10:
@ Atelier Fontana, Basel

All rights reserved. Copies and reproduction of any kind require the permission of the editor.



**Educating
Talents**
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

